Protocol Ledger

NCT04628494 · Phase III · ACTIVE NOT RECRUITING

A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

Interventional Phase III clinical trial protocol NCT04628494 sponsored by Genmab in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-01-13 Enrollment: 483 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04628494
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)483 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04628494
Protocol FieldVerified Registry Value
NCT IdentifierNCT04628494
Consolidated Lead SponsorGenmab
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment483 participants (ACTUAL)
Registered Start Date2021-01-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04628494
Hospital Research SiteLocationSite Profile
University of Kentucky/Markey Cancer CenterLexington, KYOpen Hospital Dossier ->
Wake Forest Baptist HealthWinston-Salem, NCOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI